App-Quantinova.ai

OPTICAL COHERENCE TOMOGRAPHY IN THE ASSESSMENT OF SKIN FIBROSIS IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY

D. Temiz Karadag - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Scleroderma

N/A

OPTICAL COHERENCE TOMOGRAPHY OF THE SKIN DETECTS SCLERODERMA CHANGES IN CLINICALLY UNAFFECTED SKIN: AN OPPORTUNITY FOR EARLY DETECTION OF SYSTEMIC SCLEROSIS

G. Abignano - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Scleroderma

N/A

OUTPATIENT REFERRAL WITH A POSITIVE ANCA? A SINGLE-CENTRE EVALUATION OF THE IMPACT OF IMPLEMENTING THE 2017 REVISED INTERNATIONAL CONSENSUS ON ANCA TESTING FROM 1547 NEW PATIENT REFERRALS

N. Cleaton - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Raynaud syndrome

N/A

OUTCOME OF INTERSTITIAL LUNG DISEASE (ILD) IN ANTI-PM/SCL PATIENTS WITH SYSTEMIC SCLEROSIS: RESULTS FROM AN EUSTAR CASE-CONTROL STUDY.

M. G. Lazzaroni - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

PATIENT EDUCATION IN PSORIATIC ARTHRITIS: A SERVICE EVALUATION AT ONE YEAR

K. Austin - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

PARAMETRIC CARDIAC MAGNETIC RESONANCE IMAGING IDENTIFIES ARRHYTHMOGENIC SUBSTRATES IN SYSTEMIC SCLEROSIS PATIENTS

S. I. Mavrogeni - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

N/A

PATIENT AND PUBLIC INVOLVEMENT IN CLINICAL TRIAL DESIGN

S. De Souza - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

PATIENT JOURNEY TO DIAGNOSIS OF ANKYLOSING SPONDYLITIS AND ITS TREATMENT PATTERNS ACROSS CENTRAL EASTERN EUROPE AND THE UNITED STATES

T. Korotaeva - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Non-radiographic axial spondyloarthritis

N/A

PATIENT-REPORTED OUTCOME MEASURES IN SWEDISH PATIENTS WITH RECENT-ONSET SLE VERSUS RA IN THE FIRST 60 MONTHS AFTER DIAGNOSIS

M. Bjork - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

PATIENTS WITH HYPERMOBILITY RELATED DISORDERS HAVE A SIGNIFICANT NUMBER OF ORTHOPAEDIC INTERVENTIONS ON MULTIPLE SITES AND AT A YOUNG AGE: DATA FROM A TERTIARY REFERRAL CENTRE

S. Wright - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

PATIENT PERSPECTIVE ON INTRA-ARTICULAR THERAPIES IN RMDS: RESULTS FROM A EUROPEAN SURVEY

I. Pitsillidou - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

PATTERNS OF COGNITIVE DECLINE IN RHEUMATOID ARTHRITIS: RESULTS OF CASE CONTROL STUDY NESTED IN A POPULATION-BASED COHORT

T. Toyoda - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Rheumatoid arthritis

N/A

PEER SUPPORT OF PATIENT AND PUBLIC INVOLVEMENT AND ENGAGEMENT IN RESEARCH: THE ‘RUG-BUDDY’

A. Higginbottom - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

PERCENTAGE BODY FAT HAS A STRONGER ASSOCIATION WITH BONE MINERAL DENSITY AT THE HIP AND SPINE COMPARED TO BODY MASS INDEX

C. Thurston - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

N/A

PERFUSE: A FRENCH PROSPECTIVE/RETROSPECTIVE NON-INTERVENTIONAL COHORT STUDY OF INFLIXIMAB-NAIIVE AND TRANSITIONED PATIENTS RECEIVING INFLIXIMAB BIOSIMILAR SB2; AN INTERIM ANALYSIS

B. Fautrel - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ankylosing spondylitis

Infliximab Biosimilar

PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO METHOTREXATE (FINCH1)

P. C. Taylor - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

PERIPHERAL PROTEIN BIOMARKER CHANGES FOLLOWING SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB IN METHOTREXATE NAÏVE ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS (FINCH3)

P. C. Taylor - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

PERIODONTAL DISEASES AND ITS ASSOCIATION WITH ANKYLOSING SPONDYLITIS/SPA: A SYSTEMATIC REVIEW

A. Pandey - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

PERSISTENCE OF USTEKINUMAB (UST) OR TNF INHIBITOR (TNFI) TREATMENT IN PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE LARGE, PROSPECTIVE, MULTINATIONAL, REAL-WORLD PsABio COHORT

L. Gossec - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Glucocorticoid

PERSPECTIVES ON APPROACHES TO PREDICT THE DEVELOPMENT OF RHEUMATOID ARTHRITIS: A QUANTITATIVE ASSESSMENT OF PATIENTS AND THEIR FIRST DEGREE RELATIVES

I. Wells - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Filters

45280 Abstracts